We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Liquid Biopsy Utility Reinforced in Early Cancer Trials Results

By LabMedica International staff writers
Posted on 09 May 2019
Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) supports blood-based genomic profiling but is not yet routinely implemented in the setting of a clinical phase I trials.

TARGET (Tumor chARacterisation to Guide Experimental Targeted therapy) is a molecular profiling program with the primary aim to match patients with a broad range of advanced cancers to early phase clinical trials on the basis of analysis of both somatic mutations and copy number alterations (CNA) across a 641 cancer-associated-gene panel in a single ctDNA assay.

For the analysis of the first 100 patients, investigators led by those at the University of Manchester (Manchester, UK) first designed and optimized a 641-gene liquid biopsy panel using Agilent SureSelect technology. More...
Sequenced subjects were spread over 22 tumor types, with a median age of 56 years and a median of two prior lines of therapy. The team reported that they generated ctDNA NGS data successfully in 99% of patients, compared with tumor tissue sequencing, which only worked in 95%.

The group reported that 69 non-synonymous mutations were identified in tumor tissue from 54 patients overall. Analysis of corresponding ctDNA NGS data revealed good concordance, with 54 of 69 alterations (78%) also detected in plasma. Investigators applied a 2.5% variant allele frequency (VAF) threshold for liquid biopsy variant calling, and even with this relatively high cutoff, the assay was able to identify actionable mutations in the blood of 41 of 100 patients, 11 of whom received a matched therapy. Using the 2.5% cutoff, the team saw a 75% concordance (70 of 94 cases) between ctDNA and tissue results in patients with both tumor and ctDNA data.

Among the 24 discordance cases, 20 had tumor tissue mutations that were not recapitulated in the liquid biopsy sequencing. Of these, nine were actually present in sequence reads, but fell below the VAF cutoff. Four additional individuals had ctDNA mutations that were not represented in corresponding tissue sequencing. Some of these mismatches could be ascribed to either a biological or clinical consequence.

Caroline Dive, PhD, CBE, a professor and lead author of the study, said, “Now that we have demonstrated the feasibility of matching clinical trials for patients who have not responded to previous treatments by analyzing the tumor DNA in their blood, we are working to improve our blood testing approach. We are making the test more sensitive and adding new elements to it in order to understand more about a patient's disease. We are also taking several blood samples over time to see if a faulty gene is disappearing with treatment, or if there is emergence of a new genetic fault that could lead to treatment resistance. This would allow us to stop a failing treatment and consider new options to stay a step ahead of the disease.” The study was published on April 22, 2019, in the journal Nature Medicine.

Related Links:
University of Manchester


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.